Rituximab Plus Bendamustine vs Standard Therapy for CLLRituximab Plus Bendamustine vs Standard Therapy for CLL

For patients with chronic lymphocytic leukemia (CLL), the combination of rituximab plus bendamustine was less effective than standard therapy, but it was also less toxic. Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news